Gilead Sciences GILD Q 22025 Earnings Call Transcript The Motley Fool

Gilead Sciences Q2 2025 Earnings Call: Key Highlights and Strategic Insights

Gilead Sciences, the biopharmaceutical giant renowned for its advancements in HIV, oncology, and virology treatments, held its second-quarter 2025 earnings conference call on August 8, 2025. The call was led by Chairman and CEO Daniel O'Day, alongside Chief Financial Officer Andrew Dickinson, Chief Commercial Officer Johanna Mercier, and Chief Medical Officer Merdad Parsey. The discussion provided a comprehensive overview of the company's financial performance, product portfolio updates, pipeline progress, and forward-looking strategies amid a dynamic healthcare landscape.

Starting with the financials, Gilead reported robust second-quarter results that exceeded analyst expectations. Total revenue reached $7.0 billion, marking a 6% increase year-over-year, driven primarily by strong sales in its core HIV franchise and oncology segment. Product sales, excluding the impact of Veklury (remdesivir) for COVID-19, grew by 7% to $6.8 billion. The HIV portfolio, which remains the company's largest revenue driver, generated $4.7 billion, up 3% from the prior year, largely fueled by the continued dominance of Biktarvy, Gilead's flagship single-tablet regimen for HIV treatment. Biktarvy alone accounted for $3.2 billion in sales, reflecting a 10% growth, attributed to higher demand in both U.S. and international markets, as well as successful market share gains against competitors.

In oncology, Gilead highlighted significant momentum with Trodelvy, its antibody-drug conjugate approved for metastatic triple-negative breast cancer and urothelial cancer. Trodelvy sales surged 35% to $350 million, bolstered by expanded indications and positive real-world evidence supporting its efficacy. The company also noted progress in its cell therapy offerings through Kite Pharma, with Yescarta and Tecartus contributing $450 million combined, a 15% increase, driven by broader adoption in lymphoma treatments and manufacturing efficiencies.

Liver disease products, including those for hepatitis B and C, saw more modest growth at 2%, totaling $750 million, as the market stabilizes post the peak of hepatitis C cures. Veklury sales, meanwhile, declined to $200 million, down 20% year-over-year, reflecting the waning global impact of COVID-19, though Gilead emphasized its ongoing role in pandemic preparedness.

On the profitability front, non-GAAP diluted earnings per share (EPS) came in at $2.01, surpassing consensus estimates by $0.10, with GAAP EPS at $1.61. The company attributed this to disciplined cost management, including R&D expenses of $1.4 billion (up 5% due to pipeline investments) and SG&A costs of $1.2 billion. Cash flow from operations was strong at $2.5 billion, enabling Gilead to return value to shareholders through $800 million in dividends and share repurchases. The balance sheet remains solid, with $5.5 billion in cash and equivalents, providing ample flexibility for acquisitions and R&D.

Looking ahead, Gilead raised its full-year 2025 guidance, projecting total product sales between $27.5 billion and $28.0 billion, excluding Veklury, representing 4-6% growth. This optimism stems from expected continued strength in HIV and oncology, offset by potential headwinds in virology. Management reiterated its commitment to mid-single-digit annual revenue growth through 2030, supported by a diversified portfolio and innovation pipeline.

A major focus of the call was Gilead's pipeline advancements, underscoring its strategy to expand beyond HIV into oncology, inflammation, and fibrosis. In oncology, the company provided updates on lenacapavir, its long-acting HIV prevention drug, which is also being explored for broader applications. Recent Phase 3 data from the PURPOSE trials demonstrated lenacapavir's superior efficacy in preventing HIV infections, positioning it for potential label expansions. Gilead plans to file for regulatory approvals in multiple regions by year-end, aiming to address unmet needs in PrEP (pre-exposure prophylaxis).

In the oncology space, Gilead highlighted promising data from its magrolimab program, despite earlier setbacks, with ongoing trials in myelodysplastic syndromes (MDS) showing improved response rates. The company also discussed its collaboration with Arcus Biosciences, where the anti-TIGIT antibody domvanalimab is advancing in Phase 3 trials for non-small cell lung cancer (NSCLC), with topline data expected in late 2025. Parsey emphasized the potential of this combination therapy to enhance immunotherapy outcomes, potentially disrupting the PD-1 inhibitor market dominated by players like Merck and Bristol-Myers Squibb.

On the inflammation front, Gilead is investing in its oral JAK1 inhibitor, filgotinib, for rheumatoid arthritis, with sales steadily increasing in Europe and Japan. The company also touched on its fibrosis efforts, including selonsertib for non-alcoholic steatohepatitis (NASH), where new trial designs are incorporating advanced biomarkers to improve outcomes.

Strategic initiatives were another highlight, with O'Day stressing Gilead's focus on partnerships and acquisitions to bolster its portfolio. Recent deals, such as the acquisition of a small biotech firm specializing in CAR-T cell therapies, are expected to enhance Kite's capabilities. The company is also prioritizing global access, particularly in low- and middle-income countries, through voluntary licensing agreements for generic versions of its HIV drugs.

The Q&A session addressed analyst concerns on several fronts. Regarding competitive pressures in HIV, Mercier noted that Biktarvy's market share remains above 50% in key markets, with no significant erosion from generics or rivals like GSK's Dovato. On oncology reimbursement challenges, Dickinson assured that pricing strategies are aligned with value-based care models, mitigating impacts from U.S. policy changes like the Inflation Reduction Act. Analysts probed on R&D spending, to which Parsey responded that investments are targeted at high-potential areas like antibody-drug conjugates and gene therapies, with several candidates entering pivotal trials in 2026.

O'Day closed the call by reaffirming Gilead's mission to transform patient outcomes through science, highlighting the company's resilience amid economic uncertainties and its role in addressing global health challenges, including emerging infectious diseases. He expressed confidence in delivering long-term shareholder value, with a pipeline poised for multiple approvals in the coming years.

Overall, the Q2 2025 earnings call painted a picture of a company in strong financial health, with a clear vision for growth through innovation and strategic expansion. Gilead's ability to navigate market dynamics while advancing cutting-edge therapies positions it as a leader in biopharma, though investors will watch closely for execution on pipeline milestones and any geopolitical impacts on global sales. (Word count: 928)

Read the Full The Motley Fool Article at:
https://www.fool.com/earnings/call-transcripts/2025/08/08/gilead-sciences-gild-q2-2025-earnings-call-transcript/